Assay Automation to be Presented by Catalent Biologics Expert at WCBP Symposium
SOMERSET, N.J. – January 17, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that one of its scientific experts will present at CASSS’s WCBP conference, the 23rd Symposium on the Interface of Regulatory & Analytical Sciences for Biotechnology Health Products, co-sponsored by the US Food and Drug Administration, at The Mayflower Hotel, Washington, D.C. on Jan. 29 – 31, 2019.
On Tuesday, Jan. 29 at 12:45 p.m., Mike Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present “Automated Solutions for Relative Potency Assays, (GMP and Non-GMP), Now and Future State”. In his presentation, Dr. Sadick will use case studies to discuss the benefits of assay automation and discuss Catalent’s current automation platforms, as well as exploring the potential future direction of assay automation.
Dr. Sadick coordinates and oversees bioassay, ELISA and molecular biology projects for Catalent Biologics. Previously, he managed the company’s bioassay/relative potency team for 10 years at Catalent Biologics’ facility in Kansas City, Missouri. Prior to that, Dr. Sadick ran bioassay groups at Eli Lilly and Co. and Genentech. Dr. Sadick has an extensive background in cellular biology, cellular immunology and receptor signaling, molecular biology and biochemistry. He received his master’s degree and doctorate in immunology from University of Washington in Seattle, and his bachelor’s degree in biology from Johns Hopkins University in Baltimore, Maryland.
To arrange a meeting with Dr. Sadick or any of the attending Catalent executives at the event, contact Richard Kerns at NEPR – firstname.lastname@example.org
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™